Moderna Shares Continue Slide Despite Regulatory Approval for Updated Vaccine

Regulatory Wins Fail to Lift Market Sentiment

Moderna’s stock remains under significant pressure despite achieving a critical regulatory milestone. The U.S. Food and Drug Administration recently granted approval for the company’s updated COVID-19 vaccine for the 2025-2026 season, yet this development has failed to reverse the persistent downward trend in its share price. Investors continue to offload positions, reflecting deep-seated concerns about the company’s post-pandemic trajectory.

The biotech firm, once celebrated as a pandemic hero, now confronts the harsh reality of a dramatically changed market landscape. A fundamental reassessment of vaccine manufacturers is underway, driven by evolving public health policies and adjusted vaccination recommendations across the globe. Moderna’s concentrated focus on mRNA technology leaves it particularly exposed to these sector-wide shifts.